Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
详细信息 查看全文
- 作者：Hai-Liang Zhang ; Xi-Nan Sheng ; Xue-Song Li ; Hong-Kai Wang ; Zhi-Hong Chi…
- 关键词：Metastatic renal cell carcinoma ; Sorafenib ; Sunitinib ; Prognosis ; Survival
- 刊名：BMC Cancer
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：17
- 期：1
- 全文大小：698KB
- 刊物主题：Cancer Research; Oncology; Surgical Oncology; Health Promotion and Disease Prevention; Biomedicine, general; Medicine/Public Health, general;
- 出版者：BioMed Central
- ISSN：1471-2407
- 卷排序：17
文摘
BackgroundTo compare the efficacy of sorafenib and sunitinib with regard to overall survival (OS) and progression free survival (PFS) in Chinese patients with metastatic renal cell carcinoma (mRCC).